Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: A Mayo Clinic-French Consortium Study

American Journal of Hematology

Volumn 89, Issue 12, 2014, Pages 1111-1115

  Wassie, Emnet A ^a   Itzykson, Raphael ^b   Lasho, Terra L ^a   Kosmider, Olivier ^c   Finke, Christy M ^a   Hanson, Curtis A ^a   Ketterling, Rhett P ^a   Solary, Eric ^d,e,f   Tefferi, Ayalew ^a   Patnaik, Mrinal M ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT COCHIN   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e Universite Paris Sud   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; ASXL1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHOPROTEIN; REPRESSOR PROTEIN; RIBONUCLEOPROTEIN; SF3B1 PROTEIN, HUMAN; SMALL NUCLEAR RIBONUCLEOPROTEIN; SRSF2 PROTEIN, HUMAN;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW CELL; CANCER PROGNOSIS; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME LOSS; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOGENETICS; FEMALE; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOLECULAR MAYO MODEL; MONOSOMY 7; NEUTROPHIL COUNT; NEUTROPHILIA; PRIORITY JOURNAL; TRISOMY 21; TRISOMY 8; Y CHROMOSOME; ADOLESCENT; BIOLOGICAL MODEL; CELL TRANSFORMATION; CLINICAL TRIAL; GENE EXPRESSION; GENETICS; INTERNATIONAL COOPERATION; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; NEUTROPHIL; PATHOLOGY; PROGNOSIS; RISK; SURVIVAL; VERY ELDERLY;

ABNORMAL KARYOTYPE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW CELLS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION; HUMANS; INTERNATIONAL COOPERATION; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; LEUKOCYTOSIS; MALE; MIDDLE AGED; MODELS, GENETIC; MUTATION; NEUTROPHILS; NUCLEAR PROTEINS; PHOSPHOPROTEINS; PROGNOSIS; REPRESSOR PROTEINS; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; RIBONUCLEOPROTEINS; RISK; SURVIVAL ANALYSIS;

EID: 84922393115     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23846     Document Type: Article

References (29)

1. Swederlow S, Camp E, Harris NL, Jaffe ES, Stefano PA, Stein H, Thiele J, Vardiman JW, editor. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer; 2008.
2. Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: A retrospective analysis of 213 patients. Blood 2002;99:840-849.
3. Patnaik MM, Lasho TL, Finke CM, et al. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance. Am J Hematol 2013;88:201-206.
4. Such E, Cervera J, Costa D, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 2011;96:375-383.
5. Tang G, Zhang L, Fu B, et al. Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. Am J Hematol 2014;89:813-818.
6. Alsahlawi A, Alkhateeb H, Patnaik M, et al. Monosomal karyotype predicts adverse prognosis in patients diagnosed with chronic myelomonocytic leukemia: A single-institution experience. Clin Lymphoma Myeloma Leuk 2014.
7. Patnaik MM, Hanson CA, Hodnefield J, et al. Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Leukemia 2010;25:266-270.
8. Gelsi-Boyer V, Brecqueville M, Devillier R, et al. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol 2012;5:12.
9. Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013;31:2428-2436.
10. Itzykson R, Kosmider O, Renneville A, et al. Clonal architecture of chronic myelomonocytic leukemias. Blood 2013;121:2186-2198.
11. Gelsi-Boyer V, Trouplin V, Adelaide J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009;145:788-800.
12. Patnaik MM, Padron E, LaBorde RR, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia 2013;27:1504-1510.
13. Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012;120:3080-3088.
14. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478:64-69.
15. Kar SA, Jankowska A, Makishima H, et al. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Haematologica 2013;98:107-113.
16. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002;347:481-487.
17. Kohlmann A, Grossmann V, Klein HU, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010;28:3858-3865.
18. Kuo MC, Liang DC, Huang CF, et al. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia 2009;23:1426-1431.
19. Jankowska AM, Makishima H, Tiu RV, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2011;118:3932-3941.
20. Patnaik MM, Itzykson R, Lasho TL, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: A two center study of 466 patients. Leukemia, 2014. doi: 10.1038/leu.2014.125. [Epub ahead of print]
21. Patnaik MM, Parikh SA, Hanson CA, et al. Chronic myelomonocytic leukaemia: A concise clinical and pathophysiological review. Br J Haematol 2014;165:273-286.
22. An International System for Human Cytogenetic Nomenclature (1985) ISCN 1985. Report of the Standing Committee on Human Cytogenetic Nomenclature. Birth Defects Orig Artic Ser 1985;21:1-117.
23. Patnaik MM, Padron E, LaBorde RR, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia 2013;27:1504-1510.
24. Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012;119:569-572.
25. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: A better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008;26:4791-4797.
26. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454-2465.
27. Caramazza D, Begna KH, Gangat N, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: A single center study of 433 patients. Leukemia 2011;25:82-88.
28. Martin M, Masshofer L, Temming P, et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet 2013;45:933-936.
29. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, Lowenberg B, et al. Low expression of MDS1-EVI1-like-1 (MEL1) and EVI1-like-1 (EL1) genes in favorable-risk acute myeloid leukemia. Exp Hematol 2003;31:1066-1072.